Article ID Journal Published Year Pages File Type
6143248 Virus Research 2012 7 Pages PDF
Abstract

Coxsackievirus B3 (CVB3) is the most important causal agent of viral heart muscle disease, but no specific antiviral drug is currently available. Small interfering RNA (siRNA) has been used as an antiviral therapeutic strategy via posttranscriptional gene silencing. In this study, eleven siRNAs were designed to target seven distinct regions of the CVB3 genome including VP1, VP2, VP3, 2A, 2C, 3C, and 3D. All of the siRNAs were individually transfected into HeLa cells, which were subsequently infected with CVB3. The impacts of RNA interference (RNAi) on viral replication were evaluated using five measures: cytopathic effect (CPE), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, 50% tissue culture infectious dose (TCID50), real-time RT-PCR, and Western blot. Five of the eleven siRNAs were highly efficient at inhibiting viral replication. This was especially true for siRNA-5, which targeted the ATPase 2C. However, antiviral activity varied significantly among siRNA-9, -10, and -11 even though that they all targeted the 3D region. Our results revealed several effective targets for CVB3 silencing, and provided evidence that sequences except CRE within the 2C region may also be potential targets for CVB3-specific siRNAs design. These data supported a potential role of RNA interference in future antiviral intervention therapies.

► We design eleven siRNAs targeting seven regions of CVB3 genome. ► We examine the effects of RNAi on replication of CVB3 in Hela cells. ► siRNAs exhibited different antiviral effect targeting different regions of CVB3 genome, even distinct parts of the same region. ► We find five new effective targets for CVB3 silencing. ► ATPase 2C-sepcific siRNA inhibits viral replication with the most efficiency.

Related Topics
Life Sciences Immunology and Microbiology Virology
Authors
, , , , , , , ,